EA201490047A1 - Ингаляционные фармацевтические композиции - Google Patents

Ингаляционные фармацевтические композиции

Info

Publication number
EA201490047A1
EA201490047A1 EA201490047A EA201490047A EA201490047A1 EA 201490047 A1 EA201490047 A1 EA 201490047A1 EA 201490047 A EA201490047 A EA 201490047A EA 201490047 A EA201490047 A EA 201490047A EA 201490047 A1 EA201490047 A1 EA 201490047A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
inhalation pharmaceutical
coq10
aerosol
particle
Prior art date
Application number
EA201490047A
Other languages
English (en)
Inventor
Нивен Раджин Нараин
Джон Патрик Маккук
Original Assignee
Берг Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46321512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490047(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Берг Ллк filed Critical Берг Ллк
Publication of EA201490047A1 publication Critical patent/EA201490047A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/02—Investigating particle size or size distribution
    • G01N15/0205—Investigating particle size or size distribution by optical means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/02—Investigating particle size or size distribution
    • G01N15/0205—Investigating particle size or size distribution by optical means
    • G01N15/0211—Investigating a scatter or diffraction pattern
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N2015/0038—Investigating nanoparticles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/49716—Converting

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)

Abstract

Ингаляционные фармацевтические композиции могут содержать водную дисперсию частицы, включающую в себя гидрофобное биоактивное средство (например, CoQ10), подходящую для непрерывного аэрозольного распыления. Вследствие их химического состава и способов получения фармацевтические композиции проявляют отличительные физико-химические свойства, которые обеспечивают преимущественную передачу и выход аэрозоля.
EA201490047A 2011-06-17 2012-06-18 Ингаляционные фармацевтические композиции EA201490047A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498505P 2011-06-17 2011-06-17
PCT/US2012/043001 WO2012174559A1 (en) 2011-06-17 2012-06-18 Inhalable pharmaceutical compositions

Publications (1)

Publication Number Publication Date
EA201490047A1 true EA201490047A1 (ru) 2014-08-29

Family

ID=46321512

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490047A EA201490047A1 (ru) 2011-06-17 2012-06-18 Ингаляционные фармацевтические композиции

Country Status (17)

Country Link
US (3) US10973763B2 (ru)
EP (1) EP2720680B1 (ru)
JP (3) JP5932993B2 (ru)
KR (1) KR102058256B1 (ru)
CN (2) CN107095863A (ru)
AU (2) AU2012271274B2 (ru)
CA (1) CA2839270C (ru)
CL (1) CL2013003621A1 (ru)
CO (1) CO6852076A2 (ru)
CR (1) CR20130663A (ru)
EA (1) EA201490047A1 (ru)
IL (1) IL230010B (ru)
MX (2) MX369543B (ru)
MY (1) MY183615A (ru)
PE (2) PE20180414A1 (ru)
SG (1) SG10201605008TA (ru)
WO (2) WO2012174559A1 (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892412B (zh) 2010-03-12 2015-09-30 博格制药有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
US8853189B2 (en) 2012-05-31 2014-10-07 Prima Innovations, Llc Antispasmodic 1,2-Diols and 1,2,3-triols
WO2013181639A1 (en) 2012-06-01 2013-12-05 Berg Pharma Llc Treatment of solid tumors using coenzyme q10
CN104797190B (zh) * 2012-11-15 2018-07-17 杰普呼吸技术公司 用于肺机能测量的装置和方法
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP2991634A1 (en) 2013-04-30 2016-03-09 Otitopic Inc. Dry powder formulations and methods of use
IL276423B2 (en) 2013-09-04 2024-05-01 Berg Llc Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment
WO2015055796A1 (en) 2013-10-16 2015-04-23 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
AU2014403039B2 (en) * 2014-08-08 2020-04-09 Shagnhai Hightide Biopharmaceutical, Ltd. Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof
CN105362220A (zh) * 2014-08-08 2016-03-02 深圳君圣泰生物技术有限公司 一种制剂及其制备方法、用途
ES2833749T3 (es) 2015-06-04 2021-06-15 Crititech Inc Partículas de taxano y su uso
WO2016210226A1 (en) * 2015-06-26 2016-12-29 Stc.Unm Coenzyme q10 aerosol
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
TWI648052B (zh) * 2016-04-20 2019-01-21 行政院農業委員會水產試驗所 一種水產萃取物之氣膠型微脂體及其製備方法
US11124644B2 (en) * 2016-09-01 2021-09-21 University Of Florida Research Foundation, Inc. Organic microgel system for 3D printing of silicone structures
MA52274A (fr) 2017-05-17 2021-02-24 Berg Llc Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse
EP3615145B1 (en) 2017-06-09 2024-05-15 Crititech, Inc. Compositions for use in the treatment of epithelial cysts by intracystic injection of antineoplastic particles
JP6840869B2 (ja) 2017-06-14 2021-03-10 クリチテック，インコーポレイテッド 肺障害の治療方法
EP3684338A4 (en) 2017-09-22 2021-06-23 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN111278436A (zh) 2017-10-03 2020-06-12 克里蒂泰克公司 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症
EP3563894B1 (en) * 2018-05-04 2021-12-22 Boehringer Ingelheim International GmbH Nebulizer and container
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
MA55726A (fr) * 2019-04-18 2022-02-23 Prevep Llc Associations thérapeutiques, compositions pharmaceutiques liquides, kits pour leur préparation et leurs méthodes d'utilisation
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
WO2021071967A1 (en) * 2019-10-09 2021-04-15 Island Breeze Systems Ca, Llc Compositions for pulmonary delivery of cannabinoids and associated methods and systems
US20210322339A1 (en) 2019-11-20 2021-10-21 Berg Llc Combination therapy of coenzyme q10 and radiation for treatment of glioma
EP4149410A1 (en) * 2020-05-15 2023-03-22 ELC Management LLC Shear-thinning cosmetic composition
CA3183691A1 (en) 2020-05-20 2021-11-25 Ricoh Company, Ltd. Particle containing lipid nanoparticles and method for producing same
CN111982763B (zh) * 2020-08-17 2021-05-14 上海普康药业有限公司 一种辅酶 q10 的粒度及粒度分布测定方法
US20240009208A1 (en) * 2020-10-02 2024-01-11 Receptor Holdings, Inc. Stabilization of cannabinoids within solid dosage forms
CN112972418B (zh) * 2021-05-18 2021-08-27 北京金城泰尔制药有限公司 硝呋太尔制霉素阴道软胶囊及其制备方法
WO2023154454A1 (en) * 2022-02-10 2023-08-17 Soligenix, Inc. Telmisartan nanosuspension for therapy of respiratory infections and methods of making and using same
KR102484687B1 (ko) * 2022-03-04 2023-01-05 (주)씨앤엘디 페노피브레이트를 포함하는 이상지질혈증의 예방 또는 치료용 약학 조성물

Family Cites Families (340)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525350A (en) 1975-02-20 1985-06-25 The New England Institute, Inc. Methods of stimulating host defense system with coenzymes Q4 to Q.sub.1
IT1157269B (it) 1982-03-19 1987-02-11 Seuref Ag Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
JPS58201711A (ja) 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US5220042A (en) 1984-01-26 1993-06-15 Otsuka Pharmaceutical Co., Ltd. 1,4-benzoquinone derivatives and benzene derivatives, and process for preparing the same
GB8423436D0 (en) 1984-09-17 1984-10-24 Riker Laboratories Inc Preparation of liposomes
GB8502892D0 (en) * 1985-02-05 1985-03-06 Sterwin Ag Aerosol composition
US4824669A (en) 1985-04-11 1989-04-25 Board Of Regents, The University Of Texas System Formulations of coenzyme Q10 for intravenous use
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
SE8603812D0 (sv) 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
GB8811410D0 (en) 1988-05-13 1988-06-15 Unilever Plc Treatment of skin disorders
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5962243A (en) 1990-04-18 1999-10-05 Board Of Regents, The University Of Texas System Methods for the identification of farnesyltransferase inhibitors
DE69107056T4 (de) 1990-11-14 1996-06-13 Oreal Amphiphile, nichtionische derivate des glycerins sowie die entsprechenden zwischenprodukte, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
SE502569C2 (sv) 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
US5378461A (en) 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US6461593B1 (en) 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
ATE193447T1 (de) 1992-02-24 2000-06-15 Univ East Carolina Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge
IT1256386B (it) 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
DE59406065D1 (de) 1993-03-24 1998-07-02 Ciba Geigy Ag Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
DE4410238A1 (de) 1994-03-25 1995-09-28 Beiersdorf Ag Hautpflegemittel
US20020049422A1 (en) 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
AU692547B2 (en) 1994-05-06 1998-06-11 Beckman Instruments, Inc. Liquid stable thiol activator
EP0796108A2 (en) 1994-12-06 1997-09-24 Ryan Pharmaceuticals, Inc. Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
US6005086A (en) 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
US5539021A (en) 1995-06-05 1996-07-23 The Dow Chemical Company Process for preparing high internal phase ratio emulsions and latexes derived thereof
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
DE19537027A1 (de) 1995-10-05 1997-04-10 Beiersdorf Ag Hautpflegemittel für alte Haut
US6132789A (en) 1995-12-15 2000-10-17 National Research Council Of Canada Archaeosomes, archaeosomes containing coenzyme Q10, and other types of liposomes containing coenzyme Q10 as adjuvants and as delivery vehicles
US5944012A (en) 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
DE19615577A1 (de) 1996-04-19 1997-10-23 Beiersdorf Ag Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
US5891465A (en) 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
DE19647352C2 (de) 1996-11-15 2000-06-29 Aqua Nova Getraenketechnologie Nicht alkoholisches Getränk mit einem Gehalt an Q 10
GB9625895D0 (en) 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
US20040228910A1 (en) 1997-02-11 2004-11-18 Mse Pharmazeutika Gmbh Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone
EP1007021B1 (de) 1997-02-11 2001-06-13 MSE Pharmazeutika GmbH Transdermale, orale und intravenöse zubereitungen von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
US6228891B1 (en) 1997-02-12 2001-05-08 Mse Pharmazeutika Gmbh Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
AU733692B2 (en) 1997-02-28 2001-05-24 Regents Of The University Of California, The Inhibition of cell-cell binding by lipid assemblies
US6599513B2 (en) 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US5900230A (en) 1997-08-18 1999-05-04 Squigle, Inc. Dental products to treat and prevent periodontal disease
EP1009383A1 (en) 1997-09-04 2000-06-21 Biozone Laboratories, Inc. Oral liposomal delivery system
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7348025B2 (en) * 1997-09-23 2008-03-25 Research Development Foundation Small particle liposome aerosols for delivery of anticancer drugs
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
JP4738592B2 (ja) 1997-10-31 2011-08-03 アーチ・デヴェロップメント・コーポレイション ５α−還元酵素活性を調節するための方法及び組成物
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6372880B1 (en) 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
EP2175025A1 (en) 1998-04-14 2010-04-14 Kyowa Hakko Bio Co., Ltd. Process for producing isoprenoid compounds by using microorganisms
US6503523B2 (en) 1998-05-07 2003-01-07 Gs Development A.B. Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AU755993C (en) 1998-06-19 2003-10-30 Skyepharma Canada Inc. Processes to generate submicron particles of water-insoluble compounds
DE19828081C2 (de) 1998-06-24 2000-08-10 Cognis Deutschland Gmbh W/O-Emulsionsgrundlagen
AU4908699A (en) 1998-07-16 2000-02-07 Cognis Deutschland Gmbh Use of pit emulsions
US6048886A (en) 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
IT1304406B1 (it) 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6200550B1 (en) 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
CA2260397A1 (en) 1999-01-29 2000-07-29 Atlantis Marine Inc. Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
US20040034107A1 (en) 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20020048551A1 (en) * 1999-04-06 2002-04-25 Keller Brian C. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6803193B1 (en) 1999-06-23 2004-10-12 The Penn State Research Foundation Methods to identify modulators of the mevalonate pathway in sterol synthesis
ATE304344T1 (de) 1999-07-02 2005-09-15 Cognis Ip Man Gmbh Mikrokapseln - iii
US6334999B1 (en) 1999-08-27 2002-01-01 Research Development Foundation Liposomal aerosols for delivery of chemotherapeutic retinoids to the lungs
US6479058B1 (en) 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US20030104080A1 (en) 1999-09-07 2003-06-05 Singh Parashu Ram Topical urea composition
US6630160B1 (en) 1999-09-07 2003-10-07 Genetic Services Management, Inc. Process to modulate disease risk with doses of a nutraceutical
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
US7083780B2 (en) 1999-12-11 2006-08-01 Cognis Deutschland Gmbh & Co. Kg Cosmetic composition containing hydroxyethers
WO2001045661A2 (de) 1999-12-20 2001-06-28 Cognis France, S.A. Kosmetische und/oder pharmazeutische zubereitungen
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US20020044913A1 (en) 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
FR2804864B1 (fr) 2000-02-11 2003-04-04 Serobiologiques Lab Sa Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie
DE50115609D1 (de) 2000-02-17 2010-10-14 Basf Se Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen
DE10007322A1 (de) 2000-02-17 2001-08-23 Cognis Deutschland Gmbh Perlglanzmittel
FR2805464B1 (fr) 2000-02-25 2003-02-14 Serobiologiques Lab Sa Preparations cosmetiques contenant des extraits de la plante mourera fluviatilis
DE10009996B4 (de) 2000-03-02 2005-10-13 Cognis Ip Management Gmbh Feststoffgranulate mit monodisperser Korngrößenverteilung, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung
JP2004500404A (ja) 2000-03-27 2004-01-08 カール　−　ツァイス　−　シュティフツング 生物活性ガラスを含む新規化粧品、ボディケア、洗浄剤および栄養サプリメント組成物および製造方法およびその使用
US6447760B2 (en) 2000-05-08 2002-09-10 Playtex Products, Inc. Sunless tanning compositions
US6468552B1 (en) 2000-06-02 2002-10-22 Neutrogena Corporation Stabilized compositions containing oxygen-labile active agents
DE10031703A1 (de) 2000-06-29 2002-01-10 Beiersdorf Ag Verwendung von Calcium freisetzenden oder bindenden Substanzen zur gezielten Schächung oder Stärkung der Barrierefunktion der Haut
EP1170015A1 (de) 2000-07-06 2002-01-09 Laboratoires Serobiologiques(Societe Anonyme) Verwendung von Extrakten des Pilzes Grifola frondosa
DE10033022A1 (de) 2000-07-07 2002-01-17 Cognis Deutschland Gmbh Aerosole
DE10034619A1 (de) 2000-07-17 2002-01-31 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
DE10036655A1 (de) 2000-07-26 2002-02-07 Basf Ag Kosmetische oder dermatologische Zubereitungen zur Vermeidung von Hautschädigungen durch Peroxide
DE10036799A1 (de) 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
FR2813195B1 (fr) 2000-08-29 2003-04-04 Serobiologiques Lab Sa Utilisation d'extraits de la plante cassia alata dans des produits de soin
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
DE10048260A1 (de) 2000-09-29 2002-04-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung
DE10053328A1 (de) 2000-10-27 2002-05-08 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6403116B1 (en) 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
US6756062B2 (en) 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US20070003536A1 (en) 2000-11-21 2007-01-04 Zimmerman Amy C Topical skin compositions, their preparation, and their use
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
DE10064818A1 (de) 2000-12-22 2002-06-27 Basf Ag Verwendung von Chroman-Derivaten in kosmetischen oder dermatologischen Zubreitungen
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
FR2819414A1 (fr) 2001-01-15 2002-07-19 Cognis France Sa Preparations cosmetiques et/ou pharmaceutiques comprenant des extraits de plantes dites a resurrection
NL1017205C2 (nl) 2001-01-26 2002-07-29 Adriaan Emanuel Hendricus Wiel Medicinale en cosmetische toepassing van hop en co-enzym Q10.
JP2004517699A (ja) 2001-01-30 2004-06-17 ボード オブ リージェンツ ユニバーシティ オブ テキサス システム 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法
EP1377273B1 (de) 2001-02-11 2009-03-18 Aquanova Ag Verfahren zur herstellung eines isoflavon-konzentrats
US6300377B1 (en) 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
DE10113046A1 (de) 2001-03-15 2002-09-26 Beiersdorf Ag Selbstschäumende schaumförmige Zubereitungen mit organischen Hydrokolliden und partikulären hydrophobisierten und/oder ölabsorbierenden Festkörpersubstanzen
DE10113053A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen mit anorganischen Gelbildnern und organischen Hydrololloiden
DE10113050A1 (de) 2001-03-15 2002-09-19 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen organischen Hydrokolloiden
DE60211581D1 (de) 2001-03-23 2006-06-29 Oreal Hautbehandlungsmittel enthaltend Fasern und Ubichinone
US20030031688A1 (en) 2001-04-02 2003-02-13 Dipak Ghosh Cosmetic composition with improved skin moisturizing properties
US6727234B2 (en) 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
DE10118269A1 (de) 2001-04-12 2002-10-17 Cognis Deutschland Gmbh Kosmetische Zubereitungen
US6686485B2 (en) 2001-04-19 2004-02-03 Daniel David West Synthesis of coenzyme Q10, ubiquinone
US6582723B2 (en) 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP3742602B2 (ja) 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
JP4603192B2 (ja) 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
GB0111279D0 (en) 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
DE10123771B4 (de) 2001-05-16 2019-01-10 Beiersdorf Ag Verwendung von Elektrolyten zur Stärkung der Barrierefunktion der Haut
AUPR510001A0 (en) 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
EP1260212A1 (de) 2001-05-21 2002-11-27 Cognis France S.A. Kosmetische Mittel
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
EP1262167A1 (de) 2001-06-01 2002-12-04 Cognis France S.A. Kosmetische Zubereitungen enthaltend ein Extrakt von keimenden Pflanzen
US6506915B1 (en) 2001-06-14 2003-01-14 Daniel David West Synthesis of coenzyme Q10 ubiquinone
FR2826017B1 (fr) 2001-06-15 2004-06-11 Cognis France Sa Melanges de tensioactifs
SE0102380D0 (sv) 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
DE10133198A1 (de) 2001-07-07 2003-01-23 Beiersdorf Ag Kreatin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
JP2003020495A (ja) 2001-07-10 2003-01-24 Cognis Japan Ltd 油脂組成物
DE20122900U1 (de) 2001-07-12 2009-12-03 Aquanova Ag Ubichinon Konzentrat
CH695085A5 (de) 2001-07-13 2005-12-15 Mibelle Ag Cosmetics Formulierungen zur Pflege der Haut nach Laserbehandlungen und/oder chemischen Peelings und Verwendung der Formulierungen.
TWI235146B (en) 2001-07-16 2005-07-01 Kaneka Corp Method of stabilizing reduced coenzyme q10 and method of acidic crystallization
ES2294147T5 (es) 2001-07-27 2011-04-04 N.V. Nutricia Composiciones enterales para la prevención y/o tratamiento de la sepsis.
US20050142665A1 (en) 2003-12-23 2005-06-30 Boehringer Ingelheim International Gmbh Laser diffraction method for particle size distribution measurements in pharmaceutical aerosols
US7414720B2 (en) * 2001-07-27 2008-08-19 Herbert Wachtel Measuring particle size distribution in pharmaceutical aerosols
US6699464B1 (en) 2001-07-30 2004-03-02 Stiefel Laboratories, Inc. Compositions for treatment of hyperpigmentation and methods for making and using such compositions
EP1281392A1 (de) 2001-08-02 2003-02-05 Cognis France S.A. Kosmetische und/oder pharmaceutische Zubereitungen enthaltend Pflanzenextrakte
DE10139580A1 (de) 2001-08-10 2003-02-20 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C12-C40-Fettsäuren
EP1423096B1 (en) 2001-08-29 2006-08-16 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation
DE10143964A1 (de) 2001-09-07 2003-03-27 Basf Ag Emulgatorarme oder emulgatorfreie Systeme vom Typ Öl-in-Wasser mit einem Gehalt an Stabilisatoren und einem aminosubstituierten Hydroxybenzophenon
DE10143962A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
DE10143963A1 (de) 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Form von W/O-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon
WO2003024417A1 (en) 2001-09-18 2003-03-27 Ciba Specialty Chemicals Holding Inc. Use of guaiol for treating the skin
DE10150725A1 (de) 2001-10-13 2003-04-17 Cognis Deutschland Gmbh Aniontensidfreie niedrigviskose Trübungsmittel
US7560123B2 (en) 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
ES2261760T3 (es) 2001-10-26 2006-11-16 Cognis Ip Management Gmbh Solucion impregnante para toallitas cosmeticas.
US6753325B2 (en) 2001-11-06 2004-06-22 The Quigley Corporation Composition and method for prevention, reduction and treatment of radiation dermatitis
US20030105031A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
DE10155769A1 (de) 2001-11-14 2003-05-22 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
DE10160682A1 (de) 2001-12-11 2003-06-18 Cognis Deutschland Gmbh Emollients und kosmetische Zusammensetzungen
US6652891B2 (en) 2001-12-12 2003-11-25 Herbasway Laboratories, Llc Co-enzyme Q10 dietary supplement
DE10162026A1 (de) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Hochkonzentriert fließfähige Perlglanzkonzentrate
DE10162351A1 (de) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Kosmetische und/oder pharmazeutische Emulsionen
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
US20030129253A1 (en) 2002-01-03 2003-07-10 Milley Christopher J. Stable aqueous suspension
US6696082B2 (en) 2002-01-08 2004-02-24 Mccully Kilmer S. Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier
TW200302056A (en) 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
AU2003206690A1 (en) 2002-01-18 2003-07-30 Basf Aktiengesellschaft Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides
US7357918B2 (en) 2002-01-31 2008-04-15 Ciba Specialty Chemicals Corp. Micropigment mixtures
EP1474098B1 (en) 2002-02-12 2006-08-02 DSM IP Assets B.V. Sunscreen compositions as well as dihydropyridines and dihydropyranes
ES2302913T3 (es) 2002-02-14 2008-08-01 Dsm Ip Assets B.V. Formulaciones a base de coenzima q-10.
EP1340486A1 (de) 2002-03-01 2003-09-03 Cognis France S.A. Verwendung von Zuckerestern
US20030167556A1 (en) 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
WO2003075977A2 (en) 2002-03-05 2003-09-18 Cleveland State University Agglomerated particles for aerosol drug delivery
WO2003075900A2 (de) 2002-03-09 2003-09-18 Mse Pharmazeutika Gmbh Verwendung von ubichinonen zur beeinflussung der histaminwirkung zur behandlung von bronchitis, asthma, allergischen krankheiten
DE10254315A1 (de) 2002-03-15 2003-10-02 Cognis Deutschland Gmbh Emollients und kosmetische Zubereitungen
TW200304372A (en) 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Compositions for diabetes
DE10212528A1 (de) 2002-03-21 2003-10-02 Cognis Deutschland Gmbh Ölphasen für kosmetische Mittel
DE10213957A1 (de) 2002-03-28 2003-10-09 Beiersdorf Ag Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren
US7811594B2 (en) 2002-03-28 2010-10-12 Beiersdorf Ag Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions
AU2003230750A1 (en) 2002-03-29 2003-10-13 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
DE10217474A1 (de) 2002-04-19 2003-11-06 Cognis Deutschland Gmbh Sonnenschutzemulsion mit Schaumspender
KR101036058B1 (ko) 2002-04-25 2011-05-19 더 스크립스 리서치 인스티튜트 폐질환 증상의 치료 및 예방
US20060193905A1 (en) 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
EP1509209A1 (en) 2002-05-23 2005-03-02 UMD, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
DE10223486A1 (de) 2002-05-27 2003-12-11 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen
EP1371355B1 (en) 2002-06-03 2006-08-02 Ciba SC Holding AG UV-protection formulations
EP1567180A4 (en) 2002-06-04 2010-03-10 Avicena Group Inc METHODS OF TREATING COGNITIVE DYSFUNCTIONS BY MODULATING BRAIN ENERGY METABOLISM
DE10226018A1 (de) 2002-06-12 2003-12-24 Cognis Deutschland Gmbh Zubereitungen mit konjugiertem Linolalkohol
US7147841B2 (en) 2002-06-17 2006-12-12 Ciba Specialty Chemicals Corporation Formulation of UV absorbers by incorporation in solid lipid nanoparticles
WO2004003564A2 (de) 2002-06-26 2004-01-08 Europroteome Ag Tumormarker und ihre verwendung zur diagnose und therapie von tumorerkrankungen
WO2004010958A2 (en) 2002-07-31 2004-02-05 Shaklee Corporation A method for maximizing scalp health and inducing enhanced visual and tactile hair quality
DE10245506A1 (de) * 2002-09-27 2004-04-08 Mcs Micro Carrier Systems Gmbh Zielgerichtete Formulierungen
US6953786B2 (en) 2002-10-01 2005-10-11 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
KR100484525B1 (ko) 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
US7241456B2 (en) 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
EP1421929A3 (de) 2002-11-21 2004-11-24 Cognis Deutschland GmbH & Co. KG Emollients und kosmetische Zubereitungen
DE10255195A1 (de) 2002-11-27 2004-06-09 Lipoid Gmbh Micellare wasserlösliche Konzentrate
DE10256881A1 (de) 2002-12-05 2004-06-24 Beiersdorf Ag Neue topische Verwendung von Bis-Arylimidazo[1,2-a]thiolanderivaten
US20040110848A1 (en) 2002-12-10 2004-06-10 Peffley Dennis M Method and kit for treating cancer
CA2513006A1 (en) 2003-01-15 2004-08-05 Dow Global Technologies Inc. Drug particles obtained by freezing onto a cold surface
KR101064902B1 (ko) 2003-01-20 2011-09-16 시바 홀딩 인코포레이티드 Ｕｖ 흡수제로서 트리아진 유도체
US20060140970A1 (en) 2003-01-23 2006-06-29 Adam Telerman Proteic binding partners of TCTP and methods of modulating tumor reversion or cell apoptosis
US20060073106A1 (en) 2003-02-03 2006-04-06 Dsm Ip Assets B.V. Novel stabilized cinnamic ester sunscreen compositions
US7258876B2 (en) 2003-02-05 2007-08-21 Craig Bozzacco Topical composition for treating infectious conditions of skin and mucosa
CN1208052C (zh) 2003-03-20 2005-06-29 上海家化联合股份有限公司 一种辅酶q10前体脂质体及其制备方法
JP4764817B2 (ja) 2003-03-24 2011-09-07 チバ ホールディング インコーポレーテッド 対称性トリアジン誘導体
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20110318405A1 (en) 2003-06-25 2011-12-29 Charles Erwin Chemical Combination and Method for Increasing Delivery of Coenzyme Q10
US20060035981A1 (en) 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20050036976A1 (en) 2003-08-12 2005-02-17 Joel Rubin Topical skin care composition
EP1660023B1 (de) 2003-08-27 2009-01-07 Beiersdorf AG Kapsel deren kapselhülle bei topischer anwendung nicht mehr gesondert wahrnehmbar ist
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
EP1670325A1 (en) 2003-09-29 2006-06-21 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
CA2539486A1 (en) 2003-10-02 2005-04-07 Sembiosys Genetics Inc. Methods for preparing oil bodies comprising active ingredients
DE10347218A1 (de) 2003-10-10 2005-05-12 Cognis Deutschland Gmbh Sonnenschutzmittel
DE10347940A1 (de) 2003-10-15 2005-05-19 Cognis Deutschland Gmbh & Co. Kg Selbstemulgierende Zubereitungen
WO2005041945A1 (ja) 2003-10-31 2005-05-12 Kaneka Corporation 還元型補酵素ｑ含有組成物
EP1682228B1 (en) 2003-11-05 2009-12-02 DSM IP Assets B.V. Light protecting composition with reduced total amount of uv filter containing a polysiloxane-based uv filter
US20050100537A1 (en) 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
TW200524541A (en) 2003-11-17 2005-08-01 Cargill Inc Lecithin-containing granular compositions and methods of their preparation
DE20320413U1 (de) 2003-11-17 2004-08-26 Beiersdorf Ag Kosmetikum mit empfindlichen Inhaltsstoffen
ES2235642B2 (es) 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
ME01881B (me) 2004-01-22 2014-12-20 Univ Miami Topijske formulacije koenzima q10 i postupci upotrebe
US20050226947A1 (en) 2004-02-04 2005-10-13 Dale Kern Agents for sequestering serum aging factors and uses therefore
AU2005213895A1 (en) 2004-02-19 2005-09-01 Chemaphor Inc. Topical formulations for the treatment of skin conditions
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
DE102004020627A1 (de) 2004-03-23 2005-10-13 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen
DE102004014615A1 (de) 2004-03-23 2005-10-13 Beiersdorf Ag Taurinhaltige Zubereitungen zur Verbesserung der Hautbarriere
AU2005236840B9 (en) 2004-04-06 2009-12-10 Basf Aktiengesellschaft Cosmetic formulations comprising ZnO nanoparticles
US20050226858A1 (en) 2004-04-09 2005-10-13 Kaneka Corporation Compositions containing reduced coenzyme Q10 and carotenoid
US7723569B2 (en) 2004-04-30 2010-05-25 National Institute Of Agrobiological Sciences Method for producing ubiquinone-10 in plant
RU2375053C2 (ru) 2004-05-18 2009-12-10 Кемийски Инштитут Новая водорастворимая форма коэнзима q10 в форме комплекса включения с бета-циклодекстрином, способ ее получения и ее применение
CN101001633A (zh) 2004-05-21 2007-07-18 特兰萨夫公司 肺病和肺病前期病症的治疗
NZ551366A (en) 2004-05-24 2009-01-31 Basf Ag Keratin-binding polypeptides
CN101005828B (zh) 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
ATE415976T1 (de) 2004-06-18 2008-12-15 Symrise Gmbh & Co Kg Brombeerextrakt
EP1784172A4 (en) 2004-06-21 2007-12-19 Hutchison Medipharma Entpr Ltd CANCER CHEMOTHERAPY
JP2008504319A (ja) 2004-06-28 2008-02-14 ディーエスエム アイピー アセッツ ビー．ブイ． タンパク質水解物を含有する化粧品組成物
ES2511490T3 (es) 2004-07-01 2014-10-22 E-L Management Corp. Composiciones cosméticas y procedimientos que contienen un agente de bronceado y ácido ursólico encapsulado en liposoma
JP2006070016A (ja) 2004-08-02 2006-03-16 Kaneka Corp 還元型補酵素ｑを含有する美白用組成物
US20060051462A1 (en) 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
US7288263B2 (en) 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
EP1809272A4 (en) 2004-10-18 2008-01-02 Maroon Biotech Corp METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
CN101052659B (zh) 2004-11-02 2011-11-23 帝斯曼知识产权资产管理有限公司 用于遮光制品的添加剂
GB0424891D0 (en) 2004-11-11 2004-12-15 Boots Co Plc Topical compositions
EP1811977B1 (en) 2004-11-16 2018-01-10 Bioavailability, Inc. High concentration self-microemulsifying coenzyme q10 preparations for nutritional use
US20060127384A1 (en) 2004-12-09 2006-06-15 Sergio Capaccioli Coenzyme Q10 as antiapoptotic agent
US20060154993A1 (en) 2004-12-17 2006-07-13 Littarru Gian P Method for treating and preventing male infertility
NO20045674D0 (no) 2004-12-28 2004-12-28 Uni I Oslo Thin films prepared with gas phase deposition technique
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
CN102008729A (zh) 2005-01-07 2011-04-13 日本乐敦制药株式会社 外用组合物
US20080207560A1 (en) 2005-01-07 2008-08-28 Ayako Harada Composition For External Use
US20060188492A1 (en) 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
WO2006079216A1 (en) * 2005-01-28 2006-08-03 Bc Cancer Agency Liposomal compositions for parenteral delivery of agents
DE102005007980A1 (de) 2005-02-22 2006-02-23 Clariant Gmbh Kosmetische, pharmazeutische oder dermatologische Zubereitungen enthaltend Copolymerwachse
US20060198830A1 (en) 2005-03-01 2006-09-07 Siddharth Shastri Ubiquinone composition and a container for its convenient transport and storage
JP2008534619A (ja) 2005-04-01 2008-08-28 ザイムス， エルエルシー ＣｏＱ１０を送達システムとして使用する皮膚強化
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
EP1880020A4 (en) 2005-04-29 2009-05-20 Univ Tennessee Res Foundation ANTIOXIDANTIENT TEST WITH CELLULAR BIOMARKERS AND USES THEREOF
US20060280691A1 (en) 2005-06-13 2006-12-14 University Of Alberta Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery
NZ565049A (en) 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
ITPD20050224A1 (it) 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
EP1908459A4 (en) 2005-07-28 2010-07-14 Kaneka Corp COMPOSITION PREVENTING CANCER
US20070053985A1 (en) 2005-08-24 2007-03-08 Kaneka Corporation Coenzyme Q10-containing fine particle with excellent dispersibility
US20070071779A1 (en) 2005-09-26 2007-03-29 Leggit Ingenuity, Llc Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof
US20070092469A1 (en) 2005-10-26 2007-04-26 Eric Jacobs Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
US8506956B2 (en) 2005-10-31 2013-08-13 Kaneka Corporation Method for stabilizing reduced coenzyme Q10
US9265792B2 (en) 2005-11-16 2016-02-23 Patricia A. Riley Integument cell regeneration formulation
US20070248590A1 (en) 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
EP1957039A2 (en) 2005-12-09 2008-08-20 Drugtech Corporation Intravenous essential fatty acid emulsion
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
CN1823748B (zh) * 2005-12-29 2011-07-27 沈阳药科大学 辅酶q10脂质体的药物制剂及其制备工艺
US20070172436A1 (en) 2006-01-23 2007-07-26 Jerry Zhang Nonaqueous ascorbic acid compositions and methods for preparing same
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
WO2008023264A2 (en) 2006-02-09 2008-02-28 Ocean Nutrition Canada, Ltd. Coenzyme q10 production from marine bacteria
US20070184041A1 (en) 2006-02-09 2007-08-09 Burja Adam M Methods and compositions related to production of coenzyme q10
GB0603975D0 (en) 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
BRPI0708773B1 (pt) 2006-03-10 2021-10-19 Laboswiss Ag Método para solubilização, dispersão e estabilização de substâncias, produtos manufaturados de acordo com o método, bem como uso dos mesmos
US7335384B2 (en) 2006-03-17 2008-02-26 4K Nutripharma International Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
EP2005951A2 (en) 2006-03-29 2008-12-24 Kaneka Corporation Agent for improving nervous system cell functions
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
ES2639567T3 (es) 2006-04-28 2017-10-27 Kaneka Corporation Método para la estabilización de la coenzima reducida Q10
TW200810776A (en) 2006-04-28 2008-03-01 Kaneka Corp Purification method of reduced coenzyme Q10
ES2836184T3 (es) 2006-05-02 2021-06-24 Univ Miami Formulaciones tópicas de co-enzima Q10 y tratamiento de heridas
US20080020022A1 (en) 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
US20080254017A1 (en) 2006-06-19 2008-10-16 Bodybio, Inc. Methods and compositions for treating symptomes of diseases related to imbalance of essential fatty acids
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
RU2315593C1 (ru) 2006-08-02 2008-01-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Липосомальная композиция антиоксидантов для ингаляций при заболеваниях легких и верхних дыхательных путей
US8894993B2 (en) 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
EP1897530A1 (en) 2006-09-08 2008-03-12 DSMIP Assets B.V. Skin care composition
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
EP2099420B8 (en) 2006-11-17 2017-03-15 PharmaSol GmbH Nanocrystals for use in topical cosmetic formulations and method of production thereof
US20100061969A1 (en) 2006-11-22 2010-03-11 Asahi Kasei Pharma Corporation Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic
EP1927373B1 (en) * 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
JPWO2008069276A1 (ja) 2006-12-06 2010-03-25 株式会社カネカ 癌治療剤および発癌抑制剤
WO2008089408A1 (en) 2007-01-18 2008-07-24 Pinsky Mark A Materials and methods for delivering antioxidants into the skin
ES2755840T3 (es) 2007-03-22 2020-04-23 Berg Llc Formulaciones tópicas que tienen biodisponibilidad aumentada
KR100849537B1 (ko) 2007-07-04 2008-07-31 유효경 코엔자임 큐텐의 나노에멀젼 조성물
CN101091890A (zh) 2007-07-26 2007-12-26 沈阳药科大学 一种复合型乳化剂及用其制备的乳剂及其制备方法
US8139464B2 (en) * 2007-09-19 2012-03-20 Seagate Technology Llc Planar optical waveguide for heat assisted magnetic recording
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
CA2703179C (en) * 2007-10-23 2016-06-07 Transave, Inc. Liposomal vancomycin formulations
US8815567B2 (en) 2007-11-30 2014-08-26 E I Du Pont De Nemours And Company Coenzyme Q10 production in a recombinant oleaginous yeast
WO2009073843A1 (en) * 2007-12-06 2009-06-11 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
CN100536816C (zh) * 2007-12-28 2009-09-09 清华大学 一种辅酶q10纳米微囊乳液及其制备方法和应用
US8272253B2 (en) * 2008-01-22 2012-09-25 Ct Associates, Inc. Particle concentration measurement technology
US20100080785A1 (en) 2008-04-08 2010-04-01 Zymes, Llc Dried formulations
KR20100136997A (ko) 2008-04-11 2010-12-29 싸이토테크 랩스, 엘엘씨 암세포에서 아폽토시스를 유도하는 방법 및 용도
WO2010008475A2 (en) 2008-06-23 2010-01-21 Virun, Inc. Compositions containing nono-polar compounds
US20100099775A1 (en) 2008-10-17 2010-04-22 Alpharx Inc. Method for ameliorating of post-anesthetic recovery
US20100129431A1 (en) 2008-11-24 2010-05-27 Alpharx Inc. Idebenone composition for the treatment of neurological disorders
US20100215725A1 (en) 2009-02-20 2010-08-26 Joseph Schwarz Pharmaceutical composition containing idebenone for the treatment of liver disorders
KR101066197B1 (ko) 2009-04-06 2011-09-20 한국생명공학연구원 코엔자임 ｑ10 나노입자, 그 제조방법 및 상기 나노입자를 포함하는 조성물
CA2761717A1 (en) 2009-05-11 2010-11-18 Berg Biosystems, Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CN105380904A (zh) * 2010-02-11 2016-03-09 埃博灵克斯股份有限公司 用于制备气雾剂的方法和组合物
CN102892412B (zh) 2010-03-12 2015-09-30 博格制药有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
US10869843B2 (en) 2010-11-23 2020-12-22 Chemi Nutra Method for increasing muscle mass and strength
CN102008400B (zh) * 2010-11-24 2012-07-04 华中科技大学 辅酶q10纳米脂质组合物及其制备方法和用途
US20120141446A1 (en) 2010-12-02 2012-06-07 Bhiku Patel Oral Nutritional Supplement Delivery System
TWI425914B (zh) 2011-03-21 2014-02-11 Food Industry Res & Dev Inst 含高濃度奈米／次微米疏水性機能化合物之水相分散液之製備方法
MY159478A (en) 2011-05-23 2017-01-13 Malaysian Palm Oil Board A process for producing nano-capsules and nano-beadlets containing phytonutrients derived from palm oil
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
US20130280323A1 (en) 2012-04-13 2013-10-24 Banner Pharmacaps, Inc. Soft Elastic Capsules Containing Tablets and Liquid or Semisolid Fills and Methods for Their Manufacture
WO2013175266A1 (en) 2012-05-21 2013-11-28 Chemi Nutra Inc. Method for increasing muscle mass and strength
WO2014138922A1 (en) 2013-03-15 2014-09-18 Indanio Bioscience Inc. Uses for idebenone and related benzoouinones in ppar-related diseases and conditions
KR20150062802A (ko) 2013-11-29 2015-06-08 삼성전자주식회사 소수성 활성 성분을 포함하는 내부 리포좀을 포함하는 이중막 리포좀, 및 그의 용도
WO2015127537A1 (en) 2014-02-27 2015-09-03 B-Organic Films Corp. Bioactive agents included in functionalized starch having a single helix v-structure
EP3129003A1 (en) 2014-04-08 2017-02-15 University of Massachusetts Food matrices and methods of making and using

Also Published As

Publication number Publication date
US20210346291A1 (en) 2021-11-11
US10973763B2 (en) 2021-04-13
CN103732214A (zh) 2014-04-16
MX351781B (es) 2017-10-30
US20140239525A1 (en) 2014-08-28
AU2012271274A1 (en) 2014-01-16
MY183615A (en) 2021-03-03
CA2839270A1 (en) 2012-12-20
KR20140044849A (ko) 2014-04-15
SG10201605008TA (en) 2016-07-28
JP2016196462A (ja) 2016-11-24
NZ718495A (en) 2017-12-22
CO6852076A2 (es) 2014-01-30
JP2014520124A (ja) 2014-08-21
JP5932993B2 (ja) 2016-06-08
NZ619041A (en) 2016-06-24
MX2013015114A (es) 2014-02-11
AU2017204567A1 (en) 2017-07-27
MX369543B (es) 2019-11-12
PE20180414A1 (es) 2018-03-01
WO2012174557A1 (en) 2012-12-20
PE20140628A1 (es) 2014-05-30
US20120321698A1 (en) 2012-12-20
IL230010B (en) 2019-03-31
CN107095863A (zh) 2017-08-29
CR20130663A (es) 2014-03-05
CN103732214B (zh) 2017-04-12
WO2012174559A1 (en) 2012-12-20
CA2839270C (en) 2018-09-18
JP2017206524A (ja) 2017-11-24
KR102058256B1 (ko) 2020-01-22
EP2720680B1 (en) 2020-02-12
JP6158984B2 (ja) 2017-07-05
AU2012271274B2 (en) 2017-07-27
EP2720680A1 (en) 2014-04-23
CL2013003621A1 (es) 2014-04-25

Similar Documents

Publication Publication Date Title
EA201490047A1 (ru) Ингаляционные фармацевтические композиции
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
IL216468A0 (en) Compositions, methods & systems for respiratory respiratory delivery of two or more active agents
IL229260A0 (en) Preparations, methods and systems for respiratory administration of two or more active agents
EA201291306A1 (ru) Состав сухого порошка, содержащий антимускариновое средство
WO2014097151A3 (en) Autotaxin inhibitors
EA201400591A1 (ru) Ингалятор
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MX2013001677A (es) Formulaciones estables de linaclotida.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
WO2012174158A3 (en) Administration of benzodiazepine
MX2014006136A (es) Uso de aril- y hetarilcarboxamidas como endoparasiticidas.
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
WO2012156023A8 (en) Process for producing inorganic particulate material
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2011152804A3 (en) Process for dry powder formulations
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
WO2014007771A3 (en) Inhalation compositions comprising muscarinic receptor antagonist
WO2012007758A3 (en) Pharmaceutical formulations
IN2014DN07897A (ru)
CA2865491A1 (en) Spray dried formulations
EP2563785A4 (en) Compounds as Agonists Against S1P1 Receptors
TN2013000015A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor